Identification of Female-Specific Transcriptional Factors for Osteopontin Translation as a Host Factor to Determine the Difference of Clinical Features of Liver Diseases between Male and Female Patients

鉴定女性特异性骨桥蛋白翻译转录因子作为宿主因子，以确定男性和女性患者肝病临床特征的差异

• 批准号: 21590858
• 负责人: MOCHIDA Satoshi
• 金额: $ 2.91万
• 依托单位: Saitama Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21590858/
• 关键词: オステオポンチン; 転写因子; 性差; エストロゲン; C型慢性肝炎; SNP

Osteopontin promoter SNPs(nt-155,-433) were responsible for the development of sexual difference of carcinogenesis in the liver. Promoter assay using male HepG2 cells and female MCF-7 cells revealed that the activities differed between alleles of either of SNPs in both cells. Also, gel-shift assay with nuclear extracts from both cells showed 3 signals ; a common signal for both cells, male-specific SRY and a female-specific indeterminate signal. The intensity of a common signal was different between the allele of nt-155, and that of a female-specific signal was increased following addition of estrogen to MCF-7 cells. These observations suggest that sexual difference of carcinogenesis may develop through these transcriptional factors which play differently between male and female cells.

骨桥蛋白基因启动子SNP（nt-155，-433）与肝癌发生的性别差异有关。使用雄性HepG 2细胞和雌性MCF-7细胞的启动子测定揭示了两种细胞中任一SNP的等位基因之间的活性不同。此外，用来自两种细胞的核提取物进行的凝胶位移测定显示3个信号;两种细胞的共同信号，雄性特异性SRY和雌性特异性不确定信号。nt-155的等位基因之间的共同信号的强度是不同的，并且在向MCF-7细胞添加雌激素后，女性特异性信号的强度增加。这些结果表明，这些转录因子在雌雄细胞中发挥不同的作用，可能导致了癌变过程中的性别差异。

项目成果

Efficacy and safety of double filtration plasmapheresis (DFPP) in combination with interfer on therapy for chronic hepatitis C.

双滤过血浆置换（DFPP）联合干扰治疗慢性丙型肝炎的疗效和安全性。

• 发表时间: 2010
• 期刊: Hepatol Res
• 影响因子: 4.2
• 作者: Kaneko S;Mochida S;et.al
• 通讯作者: et.al

Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C

• DOI: 10.1093/hmg/ddr249
• 发表时间: 2011-09-01
• 期刊: HUMAN MOLECULAR GENETICS
• 影响因子: 3.5
• 作者: Tanaka, Yasuhito;Kurosaki, Masayuki;Mizokami, Masashi
• 通讯作者: Mizokami, Masashi

Antiviral activity, dose-response relationship, and safty of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B : A randomized, double-blind, phase II clinical traial

未经核苷治疗的日本成人慢性乙型肝炎患者口服 24 周后恩替卡韦的抗病毒活性、剂量反应关系和安全性：一项随机、双盲、II 期临床试验

• 发表时间: 2009
• 期刊: Hepatology Int 3
• 作者: Shindo M;Mochida S;et.al
• 通讯作者: et.al

Estrogen-dependent novel transfer factor as well as SRY may be involved in the sexual differrence in the development of hepatocellular carcinoma in HCV-infected patients through osteopontin expression in the liver

雌激素依赖性新型转移因子和SRY可能通过肝脏中骨桥蛋白的表达参与HCV感染患者肝细胞癌发展的性别差异

• 发表时间: 2010
• 作者: Hamaoka K;Nagoshi S;Sugawara K;Inao M;Naiki K;Nakayama N;Fujiwara K;Mochida S
• 通讯作者: Mochida S

Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy.

对从拉米夫定治疗转为稳定型慢性乙型肝炎患者进行长期恩替卡韦治疗的评估。

• 发表时间: 2010
• 期刊: Hepatol Int
• 影响因子: 6.6
• 作者: Ide T;Mochida S;et.al
• 通讯作者: et.al